NCT04361825View on ClinicalTrials.gov

Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

October 25, 2023

Study Completion Date

October 25, 2023

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Durvalumab

Durvalumab 1500mg via IV administered for every 4weeks(fixed dosing for subjects \> 30 kg body weight) in Day 1 of each cycle and AZD 6738 240mg bid per os administered in each cycle days 1 and 7. One cycle is consisted of 28 days.

Trial Locations (2)

13620

Seoul National University Bundang Hospital, Seongnam-si

Unknown

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Se-Hoon Lee

OTHER